Strides Arcolab jumps 4%, acquires Sun Pharma's CNS biz

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Moneycontrol Bureau

Shares of Strides Arcolab jumped 4 percent intraday on Monday after it has acquired central nervous system segment of erstwhile Ranbaxy.

Sun Pharmaceutical Industries and Strides Arcolab have entered into a definitive  agreement to acquire erstwhile Ranbaxy’s Solus and Solus Care for Rs 165 crore.

The deal also includes transfer of the two marketing divisions, along with employees. As per IMS July 2015 MAT report, all the products of these two divisions together accounted for approximately Rs 92 crore in sales.

Credit Suisse maintains outperform rating on the Sun Pharma stating the deal shows that low hanging fruits of Ranbaxy integration are being realised. This is also the first instance of asset sales which Sun pointed as one of the key reasons for weak sales guidance in FY16 (guidance of flat to declining sales in FY16 despite the fact that Q116 sales was 24 percent of top end of the guidance).

“The  transaction  is  subject  to  approval  from  the  Competition  Commission  of  India  and  other  customary  closing conditions. All other terms and conditions of the transaction are confidential,” Strides said in a statement to the exchanges.

At 12:00 hrs Strides Arcolab was ast Rs 1,184.00, up Rs 38.15, or 3.33 percent while Sun Pharmaceutical Industries was at Rs 900.20, down Rs 4.90, or 0.54 percent on the BSE.

Posted by Nasrin SultanaFollow @NasrinzStory